|
pubmed:abstractText |
Distinguishing an alcohol basis from a nonalcoholic basis for the clinical and histologic spectrum of steatohepatitic liver disease is difficult because of unreliability of alcohol consumption history. Unfortunately, various biomarkers have had limited utility in distinguishing alcoholic liver disease (ALD) from nonalcoholic fatty liver disease (NAFLD). Thus, the aim of our study was to create and validate a model to diagnose ALD in patients with steatohepatitis.
|
|
pubmed:affiliation |
Advanced Liver Disease Study Group and Miles and Shirley Fiterman Center for Digestive Diseases at Mayo Clinic, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
|
